Free Trial
NASDAQ:ITMN

InterMune (ITMN) Stock Price, News & Analysis

→ Here’s how to start a “Weekend Side Hustle” from your sofa (From DTI) (Ad)
Free ITMN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ITMN stock logo

About InterMune Stock (NASDAQ:ITMN)

InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

ITMN Stock News Headlines

September 24, 2023 | fool.com
Infinity Pharmaceuticals (NASDAQ: INFI)
August 25, 2023 | thestreet.com
Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today
April 23, 2024 | The Bull Report (Ad)
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
May 24, 2023 | finance.yahoo.com
Do You Own a $10 Bill Worth $70,500?
May 12, 2023 | reuters.com
INTERMUNE, INC.
March 29, 2023 | marketwatch.com
2023 Kidney (Renal) Fibrosis Market Insights and Opportunities: Estimating CAGR and Revenue Growth by 2030
January 2, 2023 | thestreet.com
Vertex Hep C Drug Improves Cure Rate in Study
December 31, 2022 | thestreet.com
Roche Buying InterMune for $8.3 Billion
April 23, 2024 | WealthPress (Ad)
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
November 27, 2022 | thestreet.com
5 Things You Must Know Before the Market Opens Wednesday
August 30, 2022 | thestreet.com
Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000
August 27, 2022 | thestreet.com
A Biotech Stock Without the Risk
July 24, 2022 | thestreet.com
Jim Cramer's 'Mad Money' Recap: A Remarkable Market
February 22, 2022 | thestreet.com
Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%
See More Headlines
Receive ITMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InterMune and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ITMN
CUSIP
45884X10
CIK
1087432
Web
N/A
Phone
+1-415-4662200
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

ITMN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of InterMune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InterMune investors own include Agios Pharmaceuticals (AGIO), Booking (BKNG), Alphabet (GOOG), Intercept Pharmaceuticals (ICPT), Align Technology (ALGN), Salesforce (CRM), 3D Systems (DDD), Gilead Sciences (GILD) and Illumina (ILMN).

This page (NASDAQ:ITMN) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
[Shocking] Elon Musk’s Plan To End Banks
Crypto 101 Media
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press